JB
PCVX icon

Julian Baker’s Vaxcyte PCVX Stock Holding History

Julian Baker’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-640,885
Closed -$23.1M – 95
2025
Q3 		$23.1M Hold
640,885
– – 0.17% 44
2025
Q2 		$20.8M Hold
640,885
– – 0.2% 37
2025
Q1 		$24.2M Buy
640,885
+592,000
+1,211% +$47.3M 0.27% 31
2024
Q4 		$4M Hold
48,885
– – 0.04% 75
2024
Q3 		$5.59M Hold
48,885
– – 0.06% 65
2024
Q2 		$3.69M Hold
48,885
– – 0.05% 73
2024
Q1 		$3.34M Hold
48,885
– – 0.04% 65
2023
Q4 		$3.07M Hold
48,885
– – 0.03% 67
2023
Q3 		$2.49M Hold
48,885
– – 0.01% 79
2023
Q2 		$2.44M Hold
48,885
– – 0.01% 90
2023
Q1 		$1.83M Hold
48,885
– – 0.01% 92
2022
Q4 		$2.34M Buy
+48,885
New +$1.92M 0.01% 95

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Julian Baker's PCVX Position: Q4 2025 in Review

Julian Baker sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 640,885 shares — an estimated $23.1M sold.

Julian Baker first reported a position in PCVX in Q4 2022 and held it in 12 quarters. The position peaked at $24.2M in Q1 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Julian Baker reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Julian Baker sold 640,885 Vaxcyte shares in Q4 2025, an estimated $23.1M.
  • Julian Baker first reported a position in Vaxcyte in Q4 2022 and held it in 12 quarters.
  • Julian Baker's Vaxcyte position peaked at $24.2M in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Baker Bros. Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.